About Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.
2BB score and signals
Ultragenyx Pharmaceutical Inc.’s current 2BB score is 24 out of 100, built from the signal categories below.
| Signal | Score | Reading |
|---|
| Activity | 12 | Very Low |
| Momentum | 50 | Stable |
| Financial strength | 29 | Weak |
| Quality | 100 | Very Strong |
| Risk | 90 | Very High |
Company facts
| CEO | Emil Kakkis |
| Headquarters | Novato, California, United States |
| Founded | 2010 |
| Employees | 1.37K |
| 52-week range | $18.29 – $42.37 |
Recent earnings
| Report date | EPS actual | EPS estimate | Revenue actual | Revenue estimate |
|---|
| 2027-02-10 | — | -0.6319 | — | $234.46M |
| 2026-11-04 | — | -1.0384 | — | $186.85M |
| 2026-08-04 | — | -1.2587 | — | $183.84M |
| 2026-05-04 | — | -1.5115 | — | $166.82M |
